Clorox (CLX)

NYSEConsumer StaplesHousehold & Personal ProductsSnapshot 2026-10-15

$87.09+1.03%

Close 2026-10-16 · 1-day change

Read the published Living FV report summary

Investment OutlookAs of Oct 15, 2026

What could strengthen or challenge Clorox’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-0.8%

+10% or more+5%0%−5%−10% or less

6.25 → 6.19 EPS · FY ending Jun 30, 2028 · 10 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 15, 2026 to Oct 15, 2026: (new ÷ prior − 1). Contributor count changed from 11 to 10; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Living FV™

Living Fair Value by QuarterlyIQ

A valuation that evolves as the business changes.

A published Living FV snapshot is not available yet. The valuation workflow remains discoverable; a market target cannot supply the missing evidence.

View Living FV report and workflow

What the Thesis Depends On

4 key conditions need to be met for the investment thesis to play out.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Meet EPS guidance for fiscal 2026	A supporting condition in Clorox's published investment case. The stated target is EPS >= $5.45.	Intact	EPS guidance cut below $5.45 or actual EPS falls below $5.45	Diluted EPS: $1.33 per share FY2026-Q4; GAAP. Published target: EPS >= $5.45. Target period is not explicitly aligned with this observation. Source published Aug 7, 20261.33 USD/share · source valueSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q4 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q4. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Successfully integrate Gojo acquisition	Clorox integrates the Gojo acquisition to expand its product range and boost growth.	Intact	Integration progress score falls below 50%	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. GOJO acquisition completed in 2026-Q3 and 2026-Q4, contributing about 3 points to fiscal year 2026 net sales and approximately 28 points to net sales growth in the Health and Wellness segment in 2026-Q4. Management consistently emphasized unlocking growth synergies and expanding the health and hygiene platform. The trajectory shows delivery on integration and growth contribution. Delivery assessment Oct 15, 2026
Manage gross margin decline	The company aims to manage gross margin decline despite higher costs, targeting about 43.2% gross margin next quarter.	Intact	Gross margin falls below 42%	Gross margin: 41.27% FY2026-Q4; GAAP. Published target: Gross margin >= 43.2%. Target period is not explicitly aligned with this observation. Source published Aug 7, 202641.273101 percent · calculatedSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q4 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q4. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 5 of last 5 quarters. Gross margin declined from 45.2% in fiscal year 2025 to 42.3% in fiscal year 2026, a 290 basis point decrease, driven by ERP transition impacts, GOJO acquisition costs, and inflationary pressures. Management has consistently emphasized cost savings to partially offset these pressures. The trajectory shows ongoing margin challenges with partial mitigation from cost savings. Delivery assessment Oct 15, 2026
Reverse sales decline and grow net sales	A primary condition in Clorox's published investment case. The stated target is Net sales >= $1.67 billion.	Intact	Net sales fall below $1.6 billion	Revenue: $1.948B FY2026-Q4; GAAP. Published target: Net sales >= $1.67 billion. Target period is not explicitly aligned with this observation. Source published Aug 7, 20261,948,000,000 USD · source valueSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q4 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q4. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-06-30 · fmp

FY2028 EPS$6.19

Unavailable → $6.19 · observed estimates

FY2028 revenue$7.81B

$7.79B → $7.81B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$7,786,384,235	4 / 10
2026-07-25	Unavailable	$7,786,384,235	4 / 10
2026-07-26	Unavailable	$7,783,611,507	3 / 9
2026-07-27	Unavailable	$7,783,611,507	3 / 9
2026-07-28	Unavailable	$7,783,611,507	3 / 9
2026-07-29	Unavailable	$7,781,003,544	3 / 9
2026-07-30	Unavailable	$7,781,003,544	3 / 9
2026-07-31	Unavailable	$7,781,003,544	3 / 9
2026-08-01	Unavailable	$7,781,003,544	3 / 9
2026-08-02	Unavailable	$7,781,003,544	3 / 9
2026-08-03	Unavailable	$7,781,003,544	3 / 9
2026-08-04	$6.45	$7,767,663,400	9 / 9
2026-08-05	$6.29	$7,781,003,544	6 / 9
2026-08-06	$6.44	$7,762,317,060	9 / 10
2026-08-07	$6.30	$7,807,446,320	7 / 10
2026-08-08	$6.30	$7,807,446,320	7 / 10
2026-08-09	$6.36	$7,793,845,610	16 / 15
2026-08-10	$6.30	$7,807,446,320	7 / 10
2026-08-11	$6.30	$7,807,446,320	7 / 10
2026-08-12	$6.30	$7,807,446,320	7 / 10
2026-08-13	$6.36	$7,793,818,940	16 / 15
2026-08-14	$6.30	$7,807,446,320	7 / 10
2026-08-15	$6.30	$7,807,446,320	10 / 12
2026-08-16	$6.30	$7,807,446,320	10 / 12
2026-08-17	$6.30	$7,807,446,320	10 / 12
2026-08-18	$6.30	$7,807,446,320	10 / 12
2026-08-19	$6.30	$7,807,446,320	10 / 12
2026-08-20	$6.28	$7,806,056,556	10 / 12
2026-08-21	$6.27	$7,814,475,068	10 / 12
2026-08-22	$6.27	$7,814,475,068	10 / 12
2026-08-23	$6.27	$7,814,475,068	10 / 12
2026-08-24	$6.27	$7,814,475,068	10 / 12
2026-08-25	$6.27	$7,814,475,068	11 / 13
2026-08-26	$6.27	$7,814,475,068	11 / 13
2026-08-27	$6.27	$7,814,475,068	11 / 13
2026-08-28	$6.27	$7,814,475,068	11 / 13
2026-08-29	$6.27	$7,814,475,068	11 / 13
2026-08-30	$6.27	$7,814,475,068	11 / 13
2026-08-31	$6.27	$7,814,475,068	11 / 13
2026-09-01	$6.27	$7,814,475,068	11 / 13
2026-09-02	$6.27	$7,814,475,068	11 / 13
2026-09-03	$6.27	$7,814,475,068	11 / 13
2026-09-04	$6.27	$7,814,475,068	11 / 13
2026-09-05	$6.27	$7,814,452,035	11 / 13
2026-09-06	$6.27	$7,814,452,035	11 / 13
2026-09-07	$6.27	$7,814,452,035	11 / 13
2026-09-08	$6.27	$7,814,452,035	11 / 13
2026-09-09	$6.27	$7,814,452,035	11 / 13
2026-09-10	$6.27	$7,814,452,035	11 / 13
2026-09-11	$6.27	$7,814,452,035	11 / 13
2026-09-12	$6.25	$7,812,158,701	10 / 13
2026-09-13	$6.25	$7,812,158,701	11 / 13
2026-09-14	$6.25	$7,812,158,701	11 / 13
2026-09-15	$6.25	$7,812,158,701	11 / 13
2026-09-16	$6.25	$7,812,158,701	11 / 13
2026-09-17	$6.25	$7,812,142,715	11 / 13
2026-09-18	$6.25	$7,812,142,715	11 / 13
2026-09-19	$6.25	$7,812,142,715	11 / 13
2026-09-20	$6.25	$7,812,142,715	11 / 13
2026-09-21	$6.25	$7,812,142,715	11 / 13
2026-09-22	$6.25	$7,812,142,715	11 / 13
2026-09-23	$6.25	$7,812,142,715	11 / 13
2026-09-24	$6.25	$7,812,142,715	11 / 13
2026-09-25	$6.25	$7,812,142,715	11 / 13
2026-09-26	$6.25	$7,812,142,715	11 / 13
2026-09-27	$6.25	$7,812,142,715	11 / 13
2026-09-28	$6.25	$7,812,142,715	11 / 13
2026-09-29	$6.25	$7,812,142,715	11 / 13
2026-09-30	$6.25	$7,812,142,715	11 / 13
2026-10-01	$6.25	$7,812,142,715	11 / 13
2026-10-02	$6.21	$7,811,876,048	10 / 13
2026-10-03	$6.21	$7,811,876,048	10 / 13
2026-10-04	$6.21	$7,811,876,048	10 / 13
2026-10-05	$6.21	$7,811,876,048	10 / 13
2026-10-06	$6.20	$7,811,349,515	10 / 13
2026-10-07	$6.19	$7,811,216,181	11 / 12
2026-10-08	$6.19	$7,811,216,181	11 / 12
2026-10-09	$6.19	$7,811,216,181	11 / 12
2026-10-10	$6.19	$7,811,216,181	11 / 12
2026-10-11	$6.19	$7,811,216,181	11 / 12
2026-10-12	$6.19	$7,811,216,181	11 / 12
2026-10-13	$6.19	$7,811,216,181	11 / 12
2026-10-14	$6.19	$7,811,213,935	11 / 12
2026-10-15	$6.19	$7,811,213,935	10 / 12

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	2	13	4
2026-06-01	2	13	4
2026-07-01	2	14	4
2026-08-01	1	14	4
2026-09-01	1	14	4
2026-10-01	1	13	4

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 1 Buy / Strong Buy · 13 Hold · 4 Sell / Strong Sell

0 upgrades0 downgrades3 maintains

Recent actions · Sep 16–Oct 15 · 3 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

UBSOct 15 · prior Aug 4

$105.00 → $91.00-13.3%

Morgan StanleyOct 15 · prior May 1

$97.00 → $87.00-10.3%

$0$57.75$115.50

0 raises · 2 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 16, 2026–Oct 15, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Meet EPS guidance for fiscal 2026Diluted EPS: $1.33 per share
Successfully integrate Gojo acquisitionDirect metric needs a verified mapping
Manage gross margin declineGross margin: 41.27%
Reverse sales decline and grow net salesRevenue: $1.948B

Next proof point

Nov 2, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.2%Typical daily move · historical

Downside history

-36.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Clorox outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 10, 2026

What kind of bet this is

This investment represents a durable compounder with a focus on health and hygiene products. The current thesis state is intact, despite some challenges in execution and market conditions.

What's priced into Clorox

The valuation suggests that the market views CLX as relatively cheap compared to its peers, with a slight expectations gap. The current pricing reflects a low level of fragility, indicating that investors are not overly concerned about immediate risks.

What the fundamentals likely do

Fundamentals are likely to show mixed results in the near term, with management facing challenges in returning to organic sales growth and managing gross margin decline. Recent performance has been neutral, but there is potential for improvement as management focuses on cost savings and integration of the GOJO acquisition.

What Clorox hinges on

The thesis hinges on management's ability to successfully integrate the GOJO acquisition and return to organic sales growth. Additionally, external factors like inflation trends and macroeconomic conditions will play a significant role in shaping future performance.